Pharming hopes for "transformational" year as it awaits Rhucin decision
This article was originally published in Scrip
Executive Summary
The Dutch biotech company Pharming believes it could be at a "transformational stage" as it looks forward to the new year with hopes of finally achieving approval for its lead product Rhucin (recombinant human C1 inhibitor) and signing commercialisation partnerships in major markets.